Hims & Hers Health, Inc. recently conducted their Q4 2025 Earnings Call, where management highlighted their transition towards a proactive, data-driven longevity model focused on diagnostics and personalized interventions. This shift has been successful, with a 65% adoption rate of personalized treatments among their 2.5 million subscribers, leading to an 11% increase in monthly revenue per subscriber.
One of the standout achievements mentioned was the rapid growth of their weight loss offering, which reached a $100 million revenue run rate in less than seven months. This success showcases the strong demand for non-injectable metabolic treatments, excluding compounded GLP-1s. Additionally, strategic verticalization through $300 million in facility investments has allowed the company to lower costs and deliver custom pharmaceutical-supplement formulas at scale.
The acquisition of Eucalyptus was a significant move for Hims & Hers Health, Inc., as it aims to establish category leadership in Australia and Japan. This strategic move positions the international segment to reach $1 billion in annual revenue within three years. Management attributes their marketing leverage gains to long-term brand investment, resulting in a 7-point year-over-year improvement in marketing as a percentage of revenue.
Looking ahead to 2026, the company anticipates a $65 million revenue headwind in Q1 due to shifting shipping cadences for weight loss products. However, this is seen as a timing issue rather than a decline in demand. Hims & Hers Health, Inc. expects newer specialties such as testosterone support, menopause care, and Labs to each surpass $100 million in annual revenue in the near future. International operations are projected to break even within 12 to 18 months, with a focus on growth in new markets like Australia and Japan.
Management is also implementing AI-driven conversational support and proactive messaging to enhance customer commitment. Early deployments have shown a 50% increase in weight logging frequency, indicating positive engagement from customers. The company’s long-term goal remains steadfast, with a target of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, supported by diverse growth engines across different geographies.
The recent acquisition of Eucalyptus represents the company’s largest to date, with payments structured through 2029 to manage dilution and cash flow. Gross margins faced a temporary decline to 72% due to international expansion costs and shorter shipping cadences in the weight loss segment. In Q4 2025, the company completed a $100 million share repurchase program and has $225 million remaining on a subsequent authorization.
In conclusion, Hims & Hers Health, Inc. continues to demonstrate strong growth and strategic acquisitions to position itself as a leader in the healthcare industry. With a focus on personalized interventions, international expansion, and innovative technologies, the company is poised for continued success in the years to come.
